Business
Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications
Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nEntest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications\n\n\n\n\n\nEntest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications\nPR Newswire\nSAN DIEGO, October 19, 2016\n\n\n\nSAN DIEGO, October 19, 2016 /PRNewswire/ --\n\nA Potential Treatment for Cancer and Arthritis in Animals \n\nEntest BioMedical's (OTCPINK: ENTB) wholly owned subsidiary Zander Therapeutics, Inc. announced the filing of a patent application covering composition of matter and methods of use related to molecules identified in their small molecule program that activate and inhibit NR2F6 ('Small Molecule Modulators of NR2F6 Activity for Animals').\n\nNR2F6 is a molecular switch known as an 'orphan nuclear receptor', which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Zander Therapeutics, Inc. has been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize veterinary applications of NR2F6.\n\nBetween 15 million and 20 million dogs are currently kept as pets in the United States. Due to advances in technology and nutrition, the average life expectancy of a dog has increased in recent years. It is estimated that over 35% of the current dog population are age 7 years old or older. With the increase in lifespan of dogs has come an increase in the incidence of cancer among the populations of dogs. According to the European Society of Veterinary Oncology and other sources, about 50% of dogs over ten years old develop a cancer-related condition at some point.  In the United States, about 6 million dogs are diagnosed with cancer each year.\n\nTypes of cancers commonly found in dogs include lymphoma, mammary tumors in females, mast cell tumors (which are a form of skin cancer), bone cancer, non-Hodgkin's lymphomas and soft issue sarcomas. Certain breeds of dogs have been shown to have higher rates of cancer; among them are golden retrievers, boxers, cocker spaniels, Saint Bernards, greyhounds, poodles, German shepherds, Rottweilers, Shetland sheepdogs, cocker spaniels, Doberman pinschers, beagles, miniature schnauzers and Shih Tzus.\n\nSimilarly, the c...